Arkansas is currently home to 726 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
NCT02089217
Recruiting
Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical ma... Read More
Gender:
All
Ages:
Between 35 years and 100 years
Trial Updated:
01/12/2024
Locations: Central Arkansas Veteran's Healthcare System, Little Rock, Arkansas
Conditions: Carotid Stenosis
Register for Updates
Phase 2b Study of ALTO-100 in MDD
NCT05712187
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
01/10/2024
Locations: Site 139, Little Rock, Arkansas
Conditions: Major Depressive Disorder
Register for Updates
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
NCT03933904
Recruiting
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
Gender:
All
Ages:
Between 2 years and 80 years
Trial Updated:
01/10/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Castleman Disease, Castleman's Disease, Multicentric
Register for Updates
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and s... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/09/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
NCT05778188
Recruiting
Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to e... Read More
Gender:
All
Ages:
10 hours and below
Trial Updated:
01/08/2024
Locations: Study Site 016, Little Rock, Arkansas
Conditions: Hypoxic-Ischemic Encephalopathy
Register for Updates
Homeless Veterans and Peer Whole Health Coaching
NCT05176977
Recruiting
Use of acute care services (e.g., hospitalizations, Emergency Department visits) contributes substantially to the cost of healthcare for Veterans. Homelessness is a robust social determinant of super utilization of acute care. The goal of this project is to test if Peer Specialists trained in Whole Health Coaching can reduce homeless Veterans' frequent use of acute care.
Gender:
All
Ages:
All
Trial Updated:
01/08/2024
Locations: Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas
Conditions: Acute Care Service Utilization, Mental Health Status, Physical Health Status, Housing
Register for Updates
Transformative Research in Diabetic Nephropathy
NCT02986984
Recruiting
This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of o... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
01/05/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Diabetic Nephropathies, Diabetic Glomerulosclerosis
Register for Updates
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT02915198
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pre-diabetes and heart or blood vessel problems.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas
Conditions: Prediabetic State, Atherosclerosis, Metformin
Register for Updates
Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products
NCT06179290
Recruiting
The purpose of the study is to evaluate changes in biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs) in adult smokers who completely switch to Ploom heated tobacco products (HTPs) compared to those who continue to smoke usual brand combustible cigarettes (UBCC).
Gender:
All
Ages:
Between 22 years and 65 years
Trial Updated:
01/04/2024
Locations: Woodland Research Northwest, Rogers, Arkansas
Conditions: Tobacco Use
Register for Updates
Phase 1 Study to Assess Safety and Efficacy of ANG003
NCT06052293
Recruiting
Randomized, parallel, active-treatment Phase 1 study of a single dose of orally administered ANG003 with a test meal in adult subjects with cystic fibrosis-related exocrine pancreatic insufficiency. The study's overall objectives are to evaluate the safety, tolerability and effect of four dose levels of ANG003.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Exocrine Pancreatic Insufficiency
Register for Updates
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
NCT05721235
Recruiting
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD). The primary objective is to determine the safety and tolerability of treating children 4 and 5 years-of-age with ADHD with Azstarys® for up 12 months. Approximately 100 subjects will be enrolled. Approximately 20 sites will participate.
Gender:
All
Ages:
Between 4 years and 5 years
Trial Updated:
01/04/2024
Locations: Preferred Research Partners (PRP), Little Rock, Arkansas
Conditions: Attention Deficit/Hyperactivity Disorder
Register for Updates
Encore PFO Closure Device - The PerFOrm Trial
NCT05537753
Recruiting
The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when compared to any investigator chosen FDA-approved PFO closure device.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
01/03/2024
Locations: Arkansas Cardiology, Little Rock, Arkansas
Conditions: Patent Foramen Ovale, Cryptogenic Stroke
Register for Updates